Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CytomX Therapeutics (CTMX) Tax Provisions (2016 - 2025)

CytomX Therapeutics' Tax Provisions history spans 9 years, with the latest figure at $54000.0 for Q4 2025.

  • For Q4 2025, Tax Provisions fell 12.9% year-over-year to $54000.0; the TTM value through Dec 2025 reached $237000.0, up 6.28%, while the annual FY2025 figure was $238000.0, 6.25% up from the prior year.
  • Tax Provisions reached $54000.0 in Q4 2025 per CTMX's latest filing, down from $58000.0 in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $2.8 million in Q3 2023 to a low of $49000.0 in Q1 2024.
  • Average Tax Provisions over 3 years is $435200.0, with a median of $61500.0 recorded in 2024.
  • Peak YoY movement for Tax Provisions: plummeted 97.84% in 2024, then increased 26.53% in 2025.
  • A 3-year view of Tax Provisions shows it stood at $1.1 million in 2023, then tumbled by 94.2% to $62000.0 in 2024, then dropped by 12.9% to $54000.0 in 2025.
  • Per Business Quant, the three most recent readings for CTMX's Tax Provisions are $54000.0 (Q4 2025), $58000.0 (Q3 2025), and $63000.0 (Q2 2025).